EVFM vs. EVLO, SXTC, SPRC, BLPH, ADTX, BDRX, ALLR, ATNF, AMPE, and APVO
Should you be buying Evofem Biosciences stock or one of its competitors? The main competitors of Evofem Biosciences include Evelo Biosciences (EVLO), China SXT Pharmaceuticals (SXTC), SciSparc (SPRC), Bellerophon Therapeutics (BLPH), Aditxt (ADTX), Biodexa Pharmaceuticals (BDRX), Allarity Therapeutics (ALLR), 180 Life Sciences (ATNF), Ampio Pharmaceuticals (AMPE), and Aptevo Therapeutics (APVO). These companies are all part of the "pharmaceutical preparations" industry.
Evofem Biosciences (NASDAQ:EVFM) and Evelo Biosciences (NASDAQ:EVLO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, dividends, analyst recommendations, risk, valuation, media sentiment, institutional ownership, earnings and profitability.
In the previous week, Evelo Biosciences had 1 more articles in the media than Evofem Biosciences. MarketBeat recorded 2 mentions for Evelo Biosciences and 1 mentions for Evofem Biosciences. Evelo Biosciences' average media sentiment score of 0.32 beat Evofem Biosciences' score of 0.00 indicating that Evelo Biosciences is being referred to more favorably in the news media.
Evofem Biosciences has a beta of -1.12, meaning that its stock price is 212% less volatile than the S&P 500. Comparatively, Evelo Biosciences has a beta of 2.03, meaning that its stock price is 103% more volatile than the S&P 500.
Evofem Biosciences has a net margin of 290.81% compared to Evelo Biosciences' net margin of 0.00%. Evelo Biosciences' return on equity of 0.00% beat Evofem Biosciences' return on equity.
Evofem Biosciences has higher revenue and earnings than Evelo Biosciences. Evelo Biosciences is trading at a lower price-to-earnings ratio than Evofem Biosciences, indicating that it is currently the more affordable of the two stocks.
0.2% of Evofem Biosciences shares are held by institutional investors. Comparatively, 0.3% of Evelo Biosciences shares are held by institutional investors. 0.2% of Evofem Biosciences shares are held by company insiders. Comparatively, 1.0% of Evelo Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Evofem Biosciences received 92 more outperform votes than Evelo Biosciences when rated by MarketBeat users. Likewise, 69.50% of users gave Evofem Biosciences an outperform vote while only 60.50% of users gave Evelo Biosciences an outperform vote.
Summary
Evofem Biosciences beats Evelo Biosciences on 8 of the 14 factors compared between the two stocks.
Get Evofem Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for EVFM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EVFM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Evofem Biosciences Competitors List
Related Companies and Tools
